How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

When this happens, it can lead to autoimmune diseases such as rheumatoid arthritis, lupus, or aplastic anemia. Scientists have long wondered why this happens and why some people with blood cancers ...

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and antitumor activity of CAR T cells.

She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...

Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...